-
Mashup Score: 6
During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Neparidze Explores Bispecific T-Cell Therapies and Their Sequencing in R/R Multiple Myeloma - 4 day(s) ago
During a Case-Based Roundtable® event, Natalia Neparidze, MD, discussed the studies that led to accelerated approval of the bispecific T-cell engagers teclistamab and elranatamab in patients with relapsed/refractory multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Minoo Battiwalla, MD, discusses recent advancements in the multiple myeloma treatment paradigm.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 44Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma - PubMed - 8 day(s) ago
B-cell maturation antigen (BCMA)-targeting therapeutics have dramatically improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, whether the mechanisms of resistance between these therapies are shared and how the identification of such mechanisms before therapy initiation could r …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 44Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma - PubMed - 8 day(s) ago
B-cell maturation antigen (BCMA)-targeting therapeutics have dramatically improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, whether the mechanisms of resistance between these therapies are shared and how the identification of such mechanisms before therapy initiation could r …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3CAR T and Bispecifics Take Center Stage in New Myeloma Trials - 28 day(s) ago
Adam D. Cohen, MD, discusses ongoing research influencing the multiple myeloma treatment landscape.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In an interview with Targeted Oncology, Doris Hansen, MD, delved into the background, methods, design, and results from 3 recent myeloma studies.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
During the morning session, the Committee will discuss supplemental biologics license application (sBLA) 125746.74 for CARVYKTI (ciltacabtagene autoleucel), …
Source: www.youtube.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 14ClinicalTrials.gov - 3 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: www.clinicaltrials.govCategories: General Medicine News, Partners & KOLsTweet-
Imp. article on "less is more" approaches in #myeloma. An ongoing "less is more" trial that I love is @AlGarfall's LimiTEC trial [https://t.co/VZqZFC1TjW], that will generate prospective data on fixed-duration [6-9 months] teclistamab. Glad to be a subsite for the trial! #mmsm https://t.co/PwibtI7DjM https://t.co/Q1qyBktWzK
-
-
Mashup Score: 7Advancing Myeloma Treatment With Blood-Based MRD Testing - 3 month(s) ago
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple #myeloma. #MMSM | @WinshipAtEmory https://t.co/xGPfpc0UAV